Details of the Drug

General Information of Drug (ID: DMWXLYZ)

Drug Name

Darifenacin

Synonyms

Enablex; Emselex; 133099-04-4; UNII-APG9819VLM; UK-88525; APG9819VLM; CHEMBL1346; CHEBI:391960; (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; darifenacine; [3H]darifenacin; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide; NCGC00168775-01; Darifenacin (USAN/INN); Darifenacinum; Darifenacina; Darifenacin [USAN:INN:BAN]; Emselex; Emselex (TN); Enablex (TN)

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Approved	[1]
Priapism	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Urinary antispasmodics

Affected Organisms

Humans and other mammals

ATC Code

G04BD10: Darifenacin

G04BD: Drugs for urinary frequency and incontinence

G04B: UROLOGICALS

G04: UROLOGICALS

G: GENITO URINARY SYSTEM AND SEX HORMONES

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

426.5

Logarithm of the Partition Coefficient (xlogp)

4.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 15% []
Clearance: The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [4]
Elimination: 12.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 13 - 19 hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.41379 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [4]
Vd: The volume of distribution (Vd) of drug is 163 L []

Chemical Identifiers

Formula: C28H30N2O2
IUPAC Name: 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide
Canonical SMILES: C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5
InChI: InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
InChIKey: HXGBXQDTNZMWGS-RUZDIDTESA-N

Cross-matching ID

PubChem CID: 444031
ChEBI ID: CHEBI:391960
CAS Number: 133099-04-4
UNII: APG9819VLM
DrugBank ID: DB00496
TTD ID: D0Y5AM
INTEDE ID: DR0417
ACDINA ID: D00169

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Muscarinic acetylcholine receptor (CHRM)	TTOXS3C	NOUNIPROTAC	Antagonist	[6]
Muscarinic acetylcholine receptor M3 (CHRM3)	TTQ13Z5	ACM3_HUMAN	Antagonist	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Overactive bladder

ICD Disease Classification

GC50.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Muscarinic acetylcholine receptor M3 (CHRM3)	DTT	CHRM3	4.61E-07	-0.59	-0.73
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Darifenacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Solifenacin.	Functional bladder disorder [GC50]	[10]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Tolterodine.	Functional bladder disorder [GC50]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Darifenacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Antagonize the effect of Darifenacin when combined with Bethanechol.	Abnormal micturition [MF50]	[11]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Darifenacin caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Darifenacin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Darifenacin caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[13]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Scopolamine.	Addictive disorder [6C50-6C5Z]	[10]
Mitotane	DMU1GX0	Moderate	Increased metabolism of Darifenacin caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[12]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Memantine.	Alzheimer disease [8A20]	[10]
Galantamine	DMEO794	Moderate	Antagonize the effect of Darifenacin when combined with Galantamine.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Darifenacin when combined with Rivastigmine.	Alzheimer disease [8A20]	[15]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Darifenacin when combined with Donepezil.	Alzheimer disease [8A20]	[15]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Darifenacin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[12]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Darifenacin caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[16]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[10]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Darifenacin caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[17]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Darifenacin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[17]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Darifenacin caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[12]
Desipramine	DMT2FDC	Moderate	Decreased metabolism of Darifenacin caused by Desipramine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[12]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Darifenacin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Darifenacin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Darifenacin caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[12]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Darifenacin and Loperamide.	Bowel habit change [ME05]	[19]
Tucatinib	DMBESUA	Major	Decreased metabolism of Darifenacin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Darifenacin when combined with Acetylcholine.	Cataract [9B10]	[20]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[21]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[21]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[21]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Darifenacin caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[12]
Dihydrocodeine	DMB0FWL	Moderate	Additive CNS depression effects by the combination of Darifenacin and Dihydrocodeine.	Chronic pain [MG30]	[22]
Alfentanil	DMVO0UB	Moderate	Additive antimotility effects by the combination of Darifenacin and Alfentanil.	Corneal disease [9A76-9A78]	[23]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Darifenacin caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[17]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Darifenacin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Darifenacin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[12]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Darifenacin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[12]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Darifenacin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[12]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Darifenacin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Darifenacin caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Cyclobenzaprine.	Depression [6A70-6A7Z]	[10]
Nortriptyline	DM4KDYJ	Moderate	Decreased metabolism of Darifenacin caused by Nortriptyline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Darifenacin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[17]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Darifenacin caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Darifenacin caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
OPC-34712	DMHG57U	Major	Decreased metabolism of Darifenacin caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Darifenacin caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Amoxapine	DMKITQE	Moderate	Decreased metabolism of Darifenacin caused by Amoxapine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Doxepin	DMPI98T	Moderate	Decreased metabolism of Darifenacin caused by Doxepin mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Maprotiline	DMPWB7T	Moderate	Decreased metabolism of Darifenacin caused by Maprotiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[12]
Nitroglycerin	DMQ2491	Minor	Decreased dissolution of Darifenacin taken sublingually caused by Nitroglycerin.	Diabetic foot ulcer [BD54]	[25]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Mepenzolate.	Digestive system disease [DE2Z]	[10]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Oxybutynine.	Discovery agent [N.A.]	[10]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Meclizine.	Dizziness and giddiness [MB48]	[10]
Fenfluramine	DM0762O	Moderate	Decreased metabolism of Darifenacin caused by Fenfluramine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Darifenacin and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[26]
Primidone	DM0WX6I	Moderate	Increased metabolism of Darifenacin caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Darifenacin caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Darifenacin caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Darifenacin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Darifenacin caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Darifenacin caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Darifenacin caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Darifenacin caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[10]
Benzthiazide	DMQWZ0H	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Benzthiazide.	Essential hypertension [BA00]	[27]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Darifenacin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Darifenacin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Darifenacin caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[12]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Darifenacin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[12]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Darifenacin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Propantheline.	Gastric ulcer [DA60]	[10]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Darifenacin caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[12]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Darifenacin when combined with Isoflurophate.	Glaucoma [9C61]	[20]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Darifenacin when combined with Pilocarpine.	Glaucoma [9C61]	[11]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Darifenacin caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[12]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Darifenacin caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[12]
Chlorothiazide	DMLHESP	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Chlorothiazide.	Heart failure [BD10-BD1Z]	[27]
Hydroflumethiazide	DMVPUQI	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[27]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Darifenacin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[17]
Telaprevir	DMMRV29	Major	Decreased metabolism of Darifenacin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[17]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Darifenacin caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Darifenacin caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Darifenacin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Darifenacin caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Darifenacin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Darifenacin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Darifenacin caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Saquinavir	DMG814N	Major	Decreased metabolism of Darifenacin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Darifenacin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Darifenacin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Darifenacin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Darifenacin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Ritonavir	DMU764S	Major	Decreased metabolism of Darifenacin caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Darifenacin caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[12]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Darifenacin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Darifenacin caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Pindolol	DMD2NV7	Moderate	Decreased metabolism of Darifenacin caused by Pindolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[12]
Indapamide	DMGN1PW	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Indapamide.	Hypertension [BA00-BA04]	[27]
Trichlormethiazide	DMHAQCO	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Trichlormethiazide.	Hypertension [BA00-BA04]	[27]
Hydrochlorothiazide	DMUSZHD	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Hydrochlorothiazide.	Hypertension [BA00-BA04]	[27]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Darifenacin and Potassium chloride.	Hypo-kalaemia [5C77]	[29]
Conivaptan	DM1V329	Major	Decreased metabolism of Darifenacin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[17]
Givosiran	DM5PFIJ	Moderate	Decreased metabolism of Darifenacin caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[12]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[10]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Amantadine.	Influenza [1E30-1E32]	[30]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Darifenacin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[31]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Darifenacin caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Propiomazine	DMKY8V1	Moderate	Decreased metabolism of Darifenacin caused by Propiomazine mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Darifenacin and ITI-007.	Insomnia [7A00-7A0Z]	[10]
R0-93877	DMM4U9G	Moderate	Antagonize the effect of Darifenacin when combined with R0-93877.	Irritable bowel syndrome [DD91]	[32]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Clidinium.	Irritable bowel syndrome [DD91]	[10]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Dicyclomine.	Irritable bowel syndrome [DD91]	[10]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Darifenacin when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[15]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Darifenacin caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[12]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Darifenacin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Ceritinib	DMB920Z	Major	Decreased metabolism of Darifenacin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Darifenacin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Darifenacin caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Darifenacin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[12]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Darifenacin caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[18]
Halofantrine	DMOMK1V	Moderate	Decreased metabolism of Darifenacin caused by Halofantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[12]
Chloroquine	DMSI5CB	Moderate	Decreased metabolism of Darifenacin caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[12]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Darifenacin caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[12]
Idelalisib	DM602WT	Major	Decreased metabolism of Darifenacin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[17]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Darifenacin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[12]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Darifenacin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[18]
Danazol	DML8KTN	Moderate	Decreased metabolism of Darifenacin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[12]
Exjade	DMHPRWG	Moderate	Increased metabolism of Darifenacin caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[12]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Darifenacin caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[12]
Neostigmine	DM6T2J3	Moderate	Antagonize the effect of Darifenacin when combined with Neostigmine.	Myasthenia gravis [8C6Y]	[33]
Pyridostigmine	DM8HO1L	Moderate	Antagonize the effect of Darifenacin when combined with Pyridostigmine.	Myasthenia gravis [8C6Y]	[33]
Edrophonium	DMCRQHB	Moderate	Antagonize the effect of Darifenacin when combined with Edrophonium.	Myasthenia gravis [8C6Y]	[33]
Ambenonium	DMOP0BL	Moderate	Antagonize the effect of Darifenacin when combined with Ambenonium.	Myasthenia gravis [8C6Y]	[33]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Darifenacin caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[12]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Darifenacin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Darifenacin caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Darifenacin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[12]
Modafinil	DMYILBE	Minor	Increased metabolism of Darifenacin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[34]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Dimenhydrinate.	Nausea/vomiting [MD90]	[10]
Promethazine	DM6I5GR	Moderate	Decreased metabolism of Darifenacin caused by Promethazine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[12]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Darifenacin caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[35]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Cyclizine.	Nausea/vomiting [MD90]	[10]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Darifenacin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Metoclopramide	DMFA5MY	Moderate	Decreased metabolism of Darifenacin caused by Metoclopramide mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[12]
Bupropion	DM5PCS7	Moderate	Decreased metabolism of Darifenacin caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[12]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Darifenacin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[12]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Darifenacin caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[12]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Darifenacin caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[12]
Metolazone	DMB39LO	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Metolazone.	Oedema [MG29]	[27]
Polythiazide	DMCH80F	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Polythiazide.	Oedema [MG29]	[27]
Levomethadyl Acetate	DM06HG5	Moderate	Additive CNS depression effects by the combination of Darifenacin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[22]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Darifenacin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[12]
Pentazocine	DM1XBHS	Moderate	Additive antimotility effects by the combination of Darifenacin and Pentazocine.	Pain [MG30-MG3Z]	[23]
Dextropropoxyphene	DM23HCX	Moderate	Additive CNS depression effects by the combination of Darifenacin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[22]
Butorphanol	DM5KYPJ	Moderate	Additive antimotility effects by the combination of Darifenacin and Butorphanol.	Pain [MG30-MG3Z]	[23]
Oxymorphone	DM65AGJ	Moderate	Additive antimotility effects by the combination of Darifenacin and Oxymorphone.	Pain [MG30-MG3Z]	[23]
Levorphanol	DMGS80V	Moderate	Additive antimotility effects by the combination of Darifenacin and Levorphanol.	Pain [MG30-MG3Z]	[23]
Dezocine	DMJDB0Y	Moderate	Additive antimotility effects by the combination of Darifenacin and Dezocine.	Pain [MG30-MG3Z]	[23]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Flavoxate.	Pain [MG30-MG3Z]	[10]
Nalbuphine	DMOSQGU	Moderate	Additive antimotility effects by the combination of Darifenacin and Nalbuphine.	Pain [MG30-MG3Z]	[23]
Methamphetamine	DMPM4SK	Moderate	Decreased metabolism of Darifenacin caused by Methamphetamine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[36]
Buprenorphine	DMPRI8G	Moderate	Additive antimotility effects by the combination of Darifenacin and Buprenorphine.	Pain [MG30-MG3Z]	[23]
Hydrocodone	DMQ2JO5	Moderate	Additive antimotility effects by the combination of Darifenacin and Hydrocodone.	Pain [MG30-MG3Z]	[23]
Oxycodone	DMXLKHV	Moderate	Additive antimotility effects by the combination of Darifenacin and Oxycodone.	Pain [MG30-MG3Z]	[23]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Biperiden.	Parkinsonism [8A00]	[10]
Levodopa	DMN3E57	Moderate	Altered absorption of Darifenacin due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[37]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Darifenacin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[38]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Methylscopolamine.	Peptic ulcer [DA61]	[10]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Darifenacin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[39]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Darifenacin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[17]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Darifenacin caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Darifenacin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Darifenacin caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Darifenacin caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[40]
Levomepromazine	DMIKFEL	Moderate	Decreased metabolism of Darifenacin caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[12]
Fluphenazine	DMIT8LX	Moderate	Decreased metabolism of Darifenacin caused by Fluphenazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[12]
Triflupromazine	DMKFQJP	Moderate	Decreased metabolism of Darifenacin caused by Triflupromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[12]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Darifenacin caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[12]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Darifenacin caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Darifenacin caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Darifenacin caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[12]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Quetiapine.	Schizophrenia [6A20]	[10]
Mesoridazine	DM2ZGAN	Moderate	Decreased metabolism of Darifenacin caused by Mesoridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Thioridazine	DM35M8J	Major	Decreased metabolism of Darifenacin caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[41]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Darifenacin caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Iloperidone.	Schizophrenia [6A20]	[10]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Paliperidone.	Schizophrenia [6A20]	[10]
Haloperidol	DM96SE0	Moderate	Decreased metabolism of Darifenacin caused by Haloperidol mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Molindone	DMAH70G	Moderate	Decreased metabolism of Darifenacin caused by Molindone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Thiothixene	DMDINC4	Moderate	Decreased metabolism of Darifenacin caused by Thiothixene mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Trifluoperazine	DMKBYWI	Moderate	Decreased metabolism of Darifenacin caused by Trifluoperazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Risperidone	DMN6DXL	Moderate	Decreased metabolism of Darifenacin caused by Risperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[12]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Asenapine.	Schizophrenia [6A20]	[10]
Pimozide	DMW83TP	Major	Decreased metabolism of Darifenacin caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[42]
Fentanyl	DM8WAHT	Moderate	Additive antimotility effects by the combination of Darifenacin and Fentanyl.	Sensation disturbance [MB40]	[23]
Sufentanil	DMU7YEL	Moderate	Additive antimotility effects by the combination of Darifenacin and Sufentanil.	Sensation disturbance [MB40]	[23]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Darifenacin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[12]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Darifenacin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[18]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Darifenacin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
Armodafinil	DMGB035	Minor	Increased metabolism of Darifenacin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Darifenacin caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[18]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Darifenacin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[43]
Pramlintide	DM0EZ9Q	Moderate	Altered absorption of Darifenacin due to GI dynamics variation caused by Pramlintide.	Type-1/2 diabete [5A10-5A11]	[44]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Atropine.	Unspecific substance harmful effect [NE6Z]	[10]
Nitrofurantoin	DM7PQIK	Minor	Altered absorption of Darifenacin due to GI dynamics variation caused by Nitrofurantoin.	Urinary tract infection [GC08]	[45]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Darifenacin caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[12]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[10]
Methdilazine	DMAUHQX	Moderate	Decreased metabolism of Darifenacin caused by Methdilazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[12]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[10]
Trimeprazine	DMEMV9D	Moderate	Decreased metabolism of Darifenacin caused by Trimeprazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[18]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[10]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[10]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Darifenacin and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[10]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Darifenacin caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[12]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Darifenacin caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[12]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Darifenacin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[12]
-----------


⏷ Show the Full List of 215 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 200	E00648	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Darifenacin 7.5 mg tablet	7.5 mg	24 HR Extended Release Oral Tablet	Oral
Darifenacin 15 mg tablet	15 mg	24 HR Extended Release Tablet	Oral
Darifenacin 15 mg tablet	15 mg	24 HR Extended Release Oral Tablet	Oral
Darifenacin 7.5 mg tablet	7.5 mg	24 HR Extended Release Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 321).
2	Darifenacin FDA Label
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
7	M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
8	The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50.
9	Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
10	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
11	Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
12	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
13	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
14	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
15	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
16	Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
17	Cerner Multum, Inc. "Australian Product Information.".
18	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
20	Multum Information Services, Inc. Expert Review Panel.
21	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
22	Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
23	Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
24	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
25	Product Information. Nitrostat (nitroglycerin). Parke-Davis, Morris Plains, NJ.
26	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
27	Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
28	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
29	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
30	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
31	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
32	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
33	Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
34	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
35	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
36	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
37	Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506]
38	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
39	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
40	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
41	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
42	Canadian Pharmacists Association.
43	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
44	Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA.
45	Jaffe JM "Effect of propantheline on nitrofurantoin absorption." J Pharm Sci 64 (1975): 1729-30. [PMID: 1185550]